Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Non-Current Assets: 2012-2025

Historic Non-Current Assets for Enanta Pharmaceuticals (ENTA) over the last 13 years, with Sep 2025 value amounting to $76.4 million.

  • Enanta Pharmaceuticals' Non-Current Assets fell 0.53% to $76.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.4 million, marking a year-over-year decrease of 0.53%. This contributed to the annual value of $76.4 million for FY2025, which is 0.53% down from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Non-Current Assets stood at $76.4 million for Q3 2025, which was down 2.46% from $78.3 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' Non-Current Assets' 5-year high stood at $129.3 million during Q2 2021, with a 5-year trough of $38.2 million in Q4 2023.
  • Moreover, its 3-year median value for Non-Current Assets was $76.4 million (2025), whereas its average is $67.9 million.
  • Within the past 5 years, the most significant YoY rise in Enanta Pharmaceuticals' Non-Current Assets was 224.03% (2021), while the steepest drop was 64.30% (2021).
  • Enanta Pharmaceuticals' Non-Current Assets (Quarterly) stood at $113.6 million in 2021, then tumbled by 43.83% to $63.8 million in 2022, then slumped by 40.16% to $38.2 million in 2023, then spiked by 110.75% to $80.5 million in 2024, then fell by 0.53% to $76.4 million in 2025.
  • Its Non-Current Assets was $76.4 million in Q3 2025, compared to $78.3 million in Q2 2025 and $80.1 million in Q1 2025.